semaj83/ctmatch_classification huggingface dataset:
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure With Preserved Ejection Fraction Pulmonary Disease Left Ventricular Hypertrophy/Hypertension Male or female; Age 18 or older Left ventricular ejection fraction ≥ 50% Symptomatic heart failure or appropriate comparator group Informed consent signed by the subject  Symptoms of active ischemia Moderate or severe mitral or aortic stenosis, or severe aortic insufficiency Serum creatinine > 3.0 or chronic hemodialysis Known chronic hepatic disease; defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels > 3.0 times the upper limit of normal as read at the local lab Severe renal dysfunction, i.e. glomerular filtration rate (GFR) <30 ml/min Atrial fibrillation Myocardial infarction within the last year Coronary bypass surgery within the last 6 months Stroke within the last 6 months Known aortic aneurysm
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive minimum age 40 years at index continuously enrolled in health plan diagnosis of COPD (ICD-9 codes of 491, 492, 496) at least one moderate exacerbation event as defined previously  Exclusionary comorbid conditions of respiratory cancer, cystic fibrosis, fibrosis due to tuberculosis (TB), bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary TB, or sarcoidosis Patients excluded if they did not receive treatment within the treatment assessment period following moderate exacerbation Receipt of maintenance medication in the pre-period Presence of treatment switch, discontinuation of index drug, or any COPD-related exacerbation during the treatment assessment period
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 0.0-15.0,  Asthma Bronchiolitis patient is admitted to the ER with shortness of breath patient management is according to standardized protocols used in Hadassah Mt. Scopus pediatric emergency department including asthma management protocol bronchiolitis management protocol ages 0 patient's parent/guardian is able to comprehend and give informed consent for participating in the study  patient has received any dose of inhaled bronchodilators in the hour prior to enrollment patient has received oral or IV steroids in a time window of 30 minutes to 5 hours prior to enrollment ventilated patients, while ventilated chest skin lesions cystic fibrosis hemodynamic instability patient's parent/guardian objects to the study protocol concurrent participation in any other clinical study physician objection
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive at least 40 years of age continuously enrolled for medical and pharmacy benefits during their pre and post-period diagnosis of COPD (ICD 491.xx, 492.xx, 496.xx)  Patients were excluded if they had MTx in the pre-index period (to ensure of MTx-naïve patients) or if they received their first MTx during 181 to 365 days of the post-period (as dispensing of MTx unlikely to be related to the index exacerbation) Additionally, patients were excluded if they had any of the following comorbid conditions anytime during the study period: respiratory cancer, cystic fibrosis, fibrosis due to, bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary tuberculosis, or sarcoidosis, and also if they had other doses (unapproved in the US) of fluticasone propionate-salmeterol xinafoate combination (100/50 mcg or 500/50 mcg) or budesonide dipropionate-formoterol fumarate fixed dose combination (any dose)
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) Inflammatory Disease Endothelial Dysfunction presence of COPD according to standard acute exacerbation of COPD according to recommended international over 40 years of age history of at least 10 py  pneumonia history or signs of congestive heart failure acute myocardial infarction thoracotomy incl. resection of lungtissue interstitial lung disease acute or chronic renal failure active malignancy autoimmune disease
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 50.0-90.0,  Chronic Obstructive Pulmonary Disease Pulmonary Hypertension Cor Pulmonale diagnosis of COPD stage II, III or IV according to the GOLD guidelines signed the informed consent  ischemic cardiopathy severe valvular disease atrial fibrillation left bundle branch block
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Community Acquired Bacterial Pneumonia age 18 years or older met ATS/ISDA rule of CABP CABP requiring hospitalization and treatment with a IV antimicrobial anticipated hospitalization for > 48 hours received ceftaroline in combination with a macrolide (clarithromycin, or azithromycin) for > 48 hours within the first 24 hours after presentation to the hospital and must have remained on therapy for at least 48 hours after admission Pneumonia Patient Outcomes Research Team (PORT)risk class III or IV  CABP PORT Risk class I, II, III CABP requiring admission to an ICU CABP suitable for outpatient therapy with an oral microbial agent confirmed or suspected respiratory tract infection attributed to a source other than CABP pathogens noninfectious case of pulmonary infiltrates or pleural empyema infection with a pathogen know to be resistant to ceftaroline or epidemiological/ clinical context suggesting a high likelihood of a resistant pathogen previous therapy with another intravenous beta-lactam for CABP for between 24 and 96 hours prior to randomization receipt of chronic concomitant systemic steroids > 40 mg of prednisone equivalent significant hepatic disease hematologic disease
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD A diagnosis of stable moderate to severe COPD as defined by GOLD (the Global Initiative for Chronic Obstructive Lung Disease) guidelines(http://www.goldcopd.org); a postbronchodilator FEV1/forced vital capacity [FVC] ratio < 70% and FEV1 ≥ 30% to <80% of the predicted value Current or former cigarette smokers with a smoking history of at least 10 pack-years  History or current diagnosis of asthma Patients who have been hospitalized for an acute COPD exacerbation within 3 months prior to Visit 1 Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks before Visit 1 Patients with any clinically significant respiratory conditions other than COPD
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) -Individuals over the age of 18 who have COPD or may be considered to be at increased risk for development of COPD  -Individuals under the age of 18
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Aged ≥40 years at initial date of COPD diagnosis COPD diagnosis with Quality Outcome Framework (QoF) approved read code has spirometry data supportive of a COPD diagnosis in the 5 years around initial date diagnosis of COPD (FEV1 % predicted) Patient has one year of data prior to initial date of COPD diagnosis Patient has a minimum of two years of data post initial date of COPD diagnosi  Patients whose initial date of COPD diagnosis is before 1997
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Interstitial Lung Disease Idiopathic Pulmonary Fibrosis Completion of informed consent Adults over the age of 18 Diagnosis of IPF per ATS guidelines Clinically stable at the time of enrollment defined as no antibiotics within the past month, with the exception of those patients currently listed for Lung Transplantation No changes in immunosuppressive regimens (if applicable) over past month  Inability to understand or complete paper and pencil questionnaires Patient not planning to return to Stanford for clinic visits
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) patients with diagnosed COPD via the medical records with code J44  terminal illness cognitive impairments
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Continuous health plan enrollment for 12 months before and after index Rx, at least one prescription for BFC or FSC during intake period, naive to ICS/LABA therapies in year prior to first prescription claim, COPD diagnosis, aged 40 or over at time of first prescription  ICS/LABA combination during pre-index period, patients with a claim for BFC and FSC on the same day, patients diagnosed with cancer, patients with long-term OCS medication use during pre-index period
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Insomnia COPD Chronic Obstructive Pulmonary Disease Fatigue mild to very severe COPD age ≥ 45 years of age with no other major healthproblems clinically stable at the time of enrollment into the study insomnia  evidence of restrictive lung disease or asthma pulse oximetry reading of < 90% at rest or < 85% at night for > 5 min evidence of a major sleep disorder other than insomnia hypnotic use acute respiratory infection within the previous 2 months presence of a potentially debilitating disease such as cancer, congestive heart failure, kidney disease, liver failure or cirrhosis; evidence of alcohol or drug abuse, musculoskeletal or degenerative nerve disease a self-reported current diagnosis of major depression or psychiatric disease or a Hospital Anxiety and Depression Scale (HADS) depression score of > 11 currently participating in pulmonary rehabilitation
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Chronic Obstructive Pulmonary Disease Endothelial Dysfunction COPD patients in stable condition ( without exacerbation min 1 months ago) Over 40 years History of at least 10 py  acute exacerbation of COPD active malignancy autoimmune disease acute myocardial infarction diabetes mellitus with late complications congestive heart failure women of childbearing potential
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease Chronic Bronchitis Written informed consent. 2. Age ≥ 40 years. 3. Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio (post-bronchodilator) <70%. 4. FEV1 (post-bronchodilator) < 80% of predicted  Moderate and severe exacerbations during the last 4 weeks. 2. Pregnancy. 3. Already participated in the study (allowed to participate only once)
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Chronic Obstructive Pulmonary Disease Diagnosis of stable COPD years or older Smoking history of at least 10 pack-years Forced Expiratory Volume in one second (FEV1) ≤ 70 % of predicted value and FEV1 / Forced Vital Capacity (FVC) < 0.70 Dyspnea ≥ 2 on the Medical Research Council (MRC) scale At least 2 exacerbations requiring prednisone treatment in the past 3 years Using a written action plan and having demonstrated adequate use of the self-administered antibiotic & prednisone (adequate use defined as prednisone started by the patient within 72 hours of symptom worsening and patient called the case-manager as recommended for following the response) Already on Advair BID (twice a day) as a maintenance therapy or able to switch over to Advair if already taking another combination medication (Symbicort) as maintenance therapy for COPD  History of asthma or allergic rhinitis before the age of 40 Regular use of oxygen, oral corticosteroids, antibiotics Unstable or life threatening co-morbid condition Medical conditions or taking medications known to affect tremor and/or heart rate (HR) Pre-existing medical conditions or on concomitant medications contraindicated with salmeterol or fluticasone propionate (e.g. monoamine oxidase inhibitors and tricyclic antidepressants, beta-adrenergic receptor blocking agents, non potassium-sparing diuretics, inhibitors of cytochrome P450 (ritonavir, ketoconazole)) On theophyllines Colonized with pseudomonas aeruginosa
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive Male or female patients 40 years of age or older All patients had to have a diagnosis of COPD and had to meet the following spirometric and static lung volume Patients had to have relatively stable, moderate to severe airway obstruction with FEV1 ≤ 50 % of predicted value FEV1/SVC ≤ 70 % All patients had to have the presence of lung hyperinflation as demonstrated by RV ≥ 125 % of predicted value Predicted normal values were calculated according to European Community Coal and Steel (ECCS) Males FEV1 predicted (L) = 4.30 x height (metres) 029 x age (years)  Patients with a history of asthma, allergic rhinitis or atopy Patients with significant diseases other than COPD were excluded. A significant disease was defined as a disease which in the opinion of the investigator may have either put the patient at risk because of participation in the study or a disease which may have influenced the results of the study or the patient's ability to participate in the study Patients with a recent history (i.e. one year or less) of myocardial infarction Patients with a recent history (i.e. three years or less) of heart failure, pulmonary oedema, or patients with cardiac arrhythmia requiring drug therapy Patients who regularly used daytime oxygen therapy for more than one hour per day and in the investigator.s opinion was unable to abstain from the use of oxygen therapy Patients with known active tuberculosis Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma were allowed Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis Patients who underwent thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reason were evaluated as per criterion No. 2 Patients with lower respiratory tract infection in the past six weeks prior to the Screening Visit (Visit 1) or during the run-in period